Rethinking GLP-1s: Balancing Benefits, Budgets, and Long-Term Health
This 2025 report explores the rapid rise in demand for GLP-1 receptor agonists—medications originally used to treat diabetes, now widely prescribed for weight loss and related chronic conditions.
Key Findings:
GLP-1s are driving record drug spending growth, surpassing even specialty drug trends. In 2024, they made up 6.7% of total drug costs, largely due to weight-loss prescriptions.
More than half of users discontinue GLP-1s within a year, often due to side effects or perceived lack of need. This raises questions about their long-term value.
Youth usage is surging, with the sharpest increases among Gen Alpha and Gen Z, sparking sustainability concerns. Experts recommend prioritizing lifestyle interventions over early pharmacologic use.
Takeaway:
GLP-1s hold promise for managing obesity and metabolic disease but present major challenges in cost, adherence, and equitable access. The report calls for comprehensive strategies combining clinical guidance, lifestyle support, and cost control to ensure sustainable use.
